There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fennec Pharmaceuticals (FENC – Research Report) and BioLife Solutions (BLFS – Research Report) with bullish sentiments.
Fennec Pharmaceuticals (FENC)
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Fennec Pharmaceuticals. The company’s shares closed last Monday at $10.02.
According to TipRanks.com, Knickerbocker is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fennec Pharmaceuticals with a $18.00 average price target, an 82.2% upside from current levels. In a report issued on May 2, Capital One Financial also reiterated a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
BioLife Solutions (BLFS)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on BioLife Solutions today and set a price target of $23.00. The company’s shares closed last Monday at $20.66.
According to TipRanks.com, Hewitt is a 1-star analyst with an average return of
Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $23.71, a 14.8% upside from current levels. In a report issued on May 10, Northland Securities also maintained a Buy rating on the stock with a $26.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FENC:
- Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- FENC Upcoming Earnings Report: What to Expect?
- Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
- Fennec price target raised to $18 from $17 at H.C. Wainwright
- Fennec Pharmaceuticals Reports Strong 2023 Growth
